opc 3911 has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
Studies (opc 3911) | Trials (opc 3911) | Recent Studies (post-2010) (opc 3911) | Studies (1-methyl-3-isobutylxanthine) | Trials (1-methyl-3-isobutylxanthine) | Recent Studies (post-2010) (1-methyl-3-isobutylxanthine) |
---|---|---|---|---|---|
16 | 0 | 0 | 5,148 | 5 | 279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abzhalelov, BB; Bronnikov, GE; Dolgacheva, LP; Zhang, SJ; Zinchenko, VP | 1 |
1 other study(ies) available for opc 3911 and 1-methyl-3-isobutylxanthine
Article | Year |
---|---|
Norepinephrine induces slow calcium signalling in murine brown preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway.
Topics: 1-Methyl-3-isobutylxanthine; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adipocytes; Adipose Tissue, Brown; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Calcium Signaling; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Isoproterenol; Isoquinolines; Male; Mice; Mice, Inbred Strains; Norepinephrine; Phosphodiesterase Inhibitors; Quinolones; Receptors, Adrenergic, beta; Sulfonamides; Thapsigargin | 2003 |